GW Pharmaceuticals plc

GW Pharmaceuticals — Investor Day (October 2014)

118 slides from GW Pharmaceuticals's investor day presentation, Oct 15, 2014

  1. Slide 1: GW Pharmaceuticals Plc R&D Day October 2014

    GW Pharmaceuticals Plc R&D Day 14 October 2014

  2. Slide 2: Forward Looking Statements and Disclaimer

    Forward Looking Statements and Disclaimer 2 This presentation contains forward - looking statements. Some of the matters discussed concerning our operations and financial performance include estimates and forward - looking statements within the meaning of the Securities Act and the Exchange Act. The

  3. Slide 3: Agenda

    Agenda 3 Topic Speaker Welcome Justin Gover CEO, GW Pharmaceuticals Session 1: Epilepsy Amanda Renz Dravet Syndrome Foundation Dr. Elizabeth Thiele Massachusetts General Hospital Harvard University Dr. Stephen Wright GW Pharmaceuticals Dr. Orrin Devinsky NYU Comprehensive Epilepsy Center NYU School

  4. Slide 4: Guest Presenter Biographies

    Guest Presenter Biographies 15 October 2014 4 Amanda Renz Amanda Renz is a founding member of Dravet Syndrome Foundation, Inc and currently serves as Board Secretary. Amanda holds a Bachelor’s in Music Education and a Master’s in Middle Level Education, but has been out of the classroom since 2008 w

  5. Slide 5: GW Pharma Overview

    GW Pharma Overview • World leader in development of plant - derived cannabinoid therapeutics ▪ Proprietary cannabinoid product platform • Commercialized product, Sativex ® ▪ Approved in 27 countries (ex - U.S.) for MS spasticity ▪ U.S. Phase 3 cancer pain trials near completion • Epidiolex ® orphan

  6. Slide 6: Meet Molly

    Meet Molly • Born 6 weeks early, on November 14, 2005 – but completely healthy • Seizures • Autism • Gait Abnormality and Difficulty • Temperature Regulation and Autonomic Dysfunction • Motor Skills Difficulty • Processing and Planning problems • Anxiety • Sleep trouble and disruption

  7. Slide 7: Dravet syndrome

    Dravet syndrome also known as - Severe Myoclonic Epilepsy of Infancy ( SMEI) • Rare and Catastrophic form of intractable epilepsy • Usually begins in the first year of life • Initial seizures often convulsive, associated with fever, and prolonged events • New seizure types emerge in the second year

  8. Slide 8: Better treatment is needed

    Better treatment is needed . Better treatment is needed. • Without better treatment, individuals with Dravet syndrome and related disorders face a diminished quality of life . • Fear of SUDEP (Sudden Unexplained Death in Epilepsy) is very real and ever present. • The constant care and supervision of

  9. Slide 9: Dravet Syndrome Foundation

    Dravet Syndrome Foundation Non - profit, grass - roots organization started in Connecticut in 2009 Mission - To aggressively raise research funds for Dravet syndrome and related epilepsies - To increase awareness of these catastrophic conditions - To provide support to affected individuals and famil

  10. Slide 10: We must work together

    We must work together, as at our heart, we all have the same goal – to make a better life for those with these syndromes. We are all connected, working to find better treatments, and one day a CURE! Patient & Patient’s Family Pharmaceutical Teams Non - Profit Awareness and Fundraising Groups Financi

  11. Slide 11: Treatments for Epilepsy: A large unmet need

    Treatments for Epilepsy: A large unmet need Elizabeth A. Thiele, MD, PhD Director, Pediatric Epilepsy Program Massachusetts General Hospital Professor of Neurology Harvard Medical School

  12. Slide 12: Epilepsy: Definitions

    Epilepsy: Definitions • Seizure: disturbance in the electrical activity of the brain • Epilepsy: two of more unprovoked seizures occurring greater than 24 hours apart • Epilepsy is a spectrum of disorders: » Many different types of seizures » Many causes » Many syndromes and types of epilepsy

  13. Slide 13: Epilepsy: Definitions - Medically intractable seizures

    Epilepsy: Definitions • Medically intractable seizures » Seizures that are not controlled by anticonvulsant medications, or are controlled only by medications that have significant side effects. » 1/3 of children with epilepsy will develop medically intractable epilepsy

  14. Slide 14: Pharmacoresistant Epilepsy

    Pharmacoresistant Epilepsy 13% 4% 36% 47% Seizure - free with 1st drug Seizure - free with 2nd drug Seizure - free with 3rd or multiple drugs Pharmacoresistant epilepsy Kwan P, Brodie MJ. N Engl J Med. 2000;342:314 - 319. Previously Untreated Epilepsy Patients (n=470)

  15. Slide 15: Anticonvulsant Drug Development: Old anticonvulsants

    Anticonvulsant Drug Development: “Old” anticonvulsant medications • 1857 Bromides • 1912 Phenobarbital • 1920’s (Ketogenic Diet) • 1938 Phenytoin • 1950’s ACTH • 1970’s Valproate, carbamazepine

  16. Slide 16: Anticonvulsant Drug Development: New FDA approved anticonvulsants

    Anticonvulsant Drug Development: “New” FDA approved anticonvulsants • 1993 Felbamate, Gabapentin • 1994 Lamotrigine • 1997 (Vagal Nerve Stimulator) • 1997 Topiramate • 1998 Tiagabine • 2000 Levetiracetam, Oxcarbazepine, Zonisamide • 2005 Pregabalin • 2009 Rufinamide, lacosamide, vigabatrin • 2010 AC

  17. Slide 17: Treatment of Seizure Types: Anticonvulsant Drugs, 2014

    Treatment of Seizure Types: Anticonvulsant Drugs, 2014 Primary Generalized Absence Myoclonic, Atonic, Tonic Tonic - Clonic Simple Partial Complex Partial Secondary Generalized Tonic - Clonic Partial Onset Ethosuximide Benzodiazepines Carbamazepine, Phenytoin, Phenobarbital, Primidone, Gabapentin, Ti

  18. Slide 18: Pharmacoresistant Epilepsy

    Pharmacoresistant Epilepsy 13% 4% 36% 47% Seizure - free with 1st drug Seizure - free with 2nd drug Seizure - free with 3rd or multiple drugs Pharmacoresistant epilepsy Kwan P, Brodie MJ. N Engl J Med. 2000;342:314 - 319. Previously Untreated Epilepsy Patients (n=470)

  19. Slide 19: MGH Expanded Access IND for Epidiolex

    MGH Expanded Access IND for Epidiolex • 26 patients enrolled in March 2014 » 25 medically intractable epilepsy » 1 refractory status epilepticus » Ages 3 - 24 years of age • Various etiologies of epilepsy

  20. Slide 20: MGH Epidiolex experience: girl with Doose syndrome

    MGH Epidiolex experience: 13 year old girl with Doose syndrome • Seizure onset at 3 years of age • Pre - Epidiolex (at time of enrollment) » On 4 anticonvulsant medications and vagus nerve stimulator » Previously on 11 other ACD, ketogenic diet, and steroid course » Daily seizure activity, with mixe

  21. Slide 21: MGH Epidiolex experience: 13 year old girl with Doose syndrome

    • On Epidiolex » Seizure free for 5 months – Previous “best seizure control” 1 - 2 days » Tolerates Epidiolex well with no apparent side effects » Now tapering other medications MGH Epidiolex experience: 13 year old girl with Doose syndrome

  22. Slide 22: MGH Epidiolex experience: girl with TSC

    MGH Epidiolex experience: 11 year old girl with TSC • Onset of seizures at 4 mo with infantile spasms • Subsequently developed refractory mixed seizure disorder, global developmental delays • Pre - Epidiolex (at time of enrollment) » On 3 ACD and vagus nerve stimulator » Previously on 12 other ACD »

  23. Slide 23: MGH Epidiolex experience: 11 year old girl with TSC

    • On Epidiolex » Seizure frequency unchanged, although seizures less intense » But, significant perceived benefits: – “ much more alert” – “significantly improved eye contact” “much more engaged and responsive ” » Plan to further increase Epidiolex dose after DEA okay MGH Epidiolex experience: 11 ye

  24. Slide 24: MGH Epidiolex experience: 20 year old boy with generalized epilepsy

    • Onset of seizures at 4 years of age » Rare seizure free days since epilepsy onset • Pre - Epidiolex (at time of enrollment) » On 5 ACD, dietary therapy, and with vagus nerve stimulator » Previously on 6 other ACD and ketogenic diet » 10 - 40 seizures per day MGH Epidiolex experience: 20 year old b

  25. Slide 25: MGH Epidiolex experience: 20 year old boy with generalized epilepsy

    • On Epidiolex » Initial dramatic decrease in seizure activity “seizure free” for several weeks » Subsequent seizure recurrence with longer duration seizures – Thought likely due to medication interactions, so adjustments made » Currently, seizure control again significantly improved MGH Epidiolex e

  26. Slide 26: Treatments for Epilepsy: a large unmet need

    Treatments for Epilepsy: a large unmet need • Incidence of epilepsy in US per year: ~150,000 new cases • Prevalence of epilepsy in US: ~2.2 million people • Prevalence of epilepsy world wide: > 65 million people IOM report on epilepsy, 2012 • Estimate of prevalence of refractory epilepsy: » US: 730,

  27. Slide 27: Epidiolex Expanded Access INDs Physician Reported Treatment Effect Data

    Epidiolex ® Expanded Access INDs P hysician Reported Treatment Effect Data 14 October 2014 Dr Stephen Wright, R&D Director

  28. Slide 28: Expanded Access Studies

    Expanded Access Studies 28 Expanded access studies are uncontrolled, carried out by individual investigators, and not typically conducted in strict compliance with Good Clinical Practices, all of which can lead to a treatment effect which may differ from that in placebo - controlled trials. Data fro

  29. Slide 29: Background and Introduction

    Background and Introduction • Expanded access INDs granted by FDA to individual pediatric epileptologists In response to unmet medical need In children and young adults with range of drug - resistant epilepsies • FDA authorization received to date for approx. 400 children at 17 US hospital sites • S

  30. Slide 30: Latest Data: Overview

    Latest Data: Overview • Treatment - resistant children and young adults (mean age 11 years) Epidiolex added to existing meds. Patients on average 3 other AEDs • Patients include extreme and rare forms of epilepsy including several patients with major congenital structural brain abnormalities • Data

  31. Slide 31: Median % Reduction in Total Seizures, All Patients

    -60% -50% -40% -30% -20% -10% 0% Week 4 Week 8 Week 12 Week 16 12 WK Av % Seizure Reduction All Patients (n=58) Median % Reduction in Total Seizures 31 - 40% - 41% - 40% - 51% (n=40) - 36% (n=58) Total Seizures = Convulsive and Non - Convulsive Weeks 1 - 4 Weeks 5 - 8 Weeks 9 - 12 Weeks 13 - 16 12 W

  32. Slide 32: All Seizures - Responder Analysis

    0% 10% 20% 30% 40% 50% 60% Week 4 Week 8 Week 12 Week 16 12 WK Av % of Patients All Patients (n=58) All Seizures - Responder Analysis 32 41% 48% 43% 55% 40% Patients with at least: 50% Responders 70% Responders 9 0% Responders Seizure Free Total Seizures = Convulsive and Non - Convulsive (n=40) (n=5

  33. Slide 33: Dravet Syndrome: Median % Reduction in Convulsive Seizures

    -80% -70% -60% -50% -40% -30% -20% -10% 0% Week 4 Week 8 Week 12 Week 16 12 WK Av % Seizure Reduction Dravet Syndrome Patients (n=12) Median % Reduction in Convulsive Seizures 33 - 72% - 62% - 51% - 56% (n=9) - 56% (n=12) Weeks 1 - 4 Weeks 5 - 8 Weeks 9 - 12 Weeks 13 - 16 12 Wk Aggregate

  34. Slide 34: Dravet Syndrome: Convulsive Seizures Responder Analysis

    0% 10% 20% 30% 40% 50% 60% 70% 80% 1 2 3 4 5 % of Patients Dravet Syndrome Patients (n=12) Convulsive Seizures - Responder Analysis 34 58% 67% 58% 56% 58% Patients with at least: 50% Responders 70% Responders 9 0% Responders Seizure Free (n=9) (n=12) Weeks 1 - 4 Weeks 5 - 8 Weeks 9 - 12 Weeks 13 - 1

  35. Slide 35: Median % Reduction in Atonic Seizures

    -80% -70% -60% -50% -40% -30% -20% -10% 0% Week 4 Week 8 Week 12 Week 16 12 WK Av % Seizure Reduction All Patients with Atonic (“Drop”) Seizures (n=12) Median % Reduction in Atonic Seizures 35 - 57% - 62% - 52% - 76% (n=10) - 52% (n=12) Weeks 1 - 4 Weeks 5 - 8 Weeks 9 - 12 Weeks 13 - 16 12 Wk Aggreg

  36. Slide 36: Atonic Seizures - Responder Analysis

    0% 10% 20% 30% 40% 50% 60% 70% 80% Week 4 Week 8 Week 12 Week 16 12 WK Av % of Patients All Patients with Atonic (“Drop”) Seizures ( n=12 ) Atonic Seizures - Responder Analysis 36 58% 67% 58% 70% 50% Patients with at least: 50% Responders 70% Responders 9 0% Responders Seizure Free (n=10) (n=12) Wee

  37. Slide 37: Safety Data

    Safety Data (151 patients, a pprox. 50 patient years treatment) • Most common AEs – all causes (10% or more of patients) - Somnolence 19% - Fatigue 11% Other AE’s in 5% or more of patients are diarrhea , decreased appetite, convulsion • 2 withdrawals due to AEs • 4 withdrawals due to lack of clinica

  38. Slide 38: Conclusions

    Conclusions • New data on additional patients is consistent with previous data on initial 27 patients • Epidiolex treatment is associated with a meaningful reduction in seizure frequency in a high proportion of patients with otherwise drug - resistant epilepsy • The response seen in the first month

  39. Slide 39: Epidiolex Clinical Observations

    Epidiolex® Clinical Observations Professor of Neurology, Neurosurgery, and Psychiatry, NYU School of Medicine Director, NYU Comprehensive Epilepsy Center Dr. Orrin Devinsky

  40. Slide 40: Clinical Program

    Clinical Program

  41. Slide 41: Overview

    Overview • F ormal development programs for Epidiolex in both Dravet syndrome and LGS • FDA Orphan Drug Designations for Epidiolex for both Dravet syndrome and LGS, as well as Fast Track Designation for Dravet syndrome • A company - sponsored IND is open with the FDA • Phase 2/3 Dravet syndrome clin

  42. Slide 42: Epidiolex in Dravet Syndrome Clinical Trials Program

    Epidiolex in Dravet Syndrome Clinical Trials Program Part A (n=30) Part B, placebo - controlled – 12 weeks (n = 80) Study 1 Study 2 Phase 3, placebo - controlled - 12 weeks (n = 120 ) DDI Study adult epilepsy patients Long - term extension study Two part study in Dravet syndrome patients on concomit

  43. Slide 43: Epidiolex in Dravet Syndrome Part A Trial Design

    3 - 11 days Titration Phase Epidiolex in Dravet Syndrome Part A Trial Design B aseline Observation P eriod Screening Randomization 28 days 21 Days High Cohort 20 mg/kg (n=8) Mid Cohort 10 mg/kg (n=8) Low Cohort 5 mg/kg (n=8) Each dose cohort randomized 4:1 Epidiolex: Placebo 43 Objective: To determi

  44. Slide 44: Epidiolex in Dravet Syndrome Part B Trial Design

    Up to 10 days Taper Period Objective: Provide pivotal evidence of safety and efficacy Epidiolex in Dravet Syndrome Part B Trial Design 44 Primary Endpoint: Average % change from baseline in convulsive seizure frequency Randomized 1:1 Placebo ( n=40 ) Epidiolex ( n=40 ) • % change non - convulsive se

  45. Slide 45: Cannabinoid medicines as the response to the need for polymodal therapies

    Cannabinoid medicines as the response to the need for polymodal therapies Vincenzo Di Marzo , PhD Director of the Institute of Biomolecular Chemistry, National Research Council of Italy, and Coordinator of the Endocannabinoid Research Group, Naples, Italy Director of Preclinical Research, GW Pharmac

  46. Slide 46: Plant cannabinoids: the post-THC era

    Plant cannabinoids : the “ post - THC ” era 15 October 2014 • Sesquiterpene analogues • Propyl analogues • Methyl analogues • Acid precursors • O thers • Over 100 phytocannabinoids

  47. Slide 47: International Research Network

    International Research Network: GW is a Pioneer in Funding Cannabinoid Research Evaluate the potential for the therapeutic use of phytocannabinoids in human disease

  48. Slide 48: Recent successes of the GW-sponsored consortium

    Recent successes of the GW - sponsored consortium GW - sponsored preclinical studies published to date > 80

  49. Slide 49: Some General Considerations on Disease

    Some General Considerations on Disease • 1 single ultra - potent “selective” compound - >1 target - >1 disease only seldom works Wrong assumption, a magic bullet may treat one of many relevant targets but this is not enough to affect a disease Instead it may cause homeostatic unbalance in organs in

  50. Slide 50: Revisiting an old Paradigm to Treat Disease

    Revisiting an old Paradigm to Treat Disease 50 3 µM 1 µM 0.3 µM 0.1 µM chemical space for target X i n vitro potency chemical space for target Z chemical space for target Y potent & selective Target area of current drug discovery desirable area for multi - target approach poly - pharm. Adapted from

  51. Slide 51: Diseases at opposite ends of unbalanced physiological modes

    Diseases are at the opposite ends of unbalanced physiological “modes” (in a time and organ - dependent manner) 51 Too much cell transmission Not enough transmission MOVEMENT DISORDERS ALZHIEMERS DISEASE EPILEPSY PAIN DEFECTIVE WOUND HEALING IMMUNODEFICIENCIES CANCER PSORIASIS ACNE NEURODEGENERATION

  52. Slide 52: Diseases caused by opposite alterations of one gene

    Diseases caused by opposite alterations of one gene may cause overlapping behavioral consequences 52 Angelman Syndrome 15q11 - q13 duplication • Gait ataxia • Tremulousness • Hypotonia • Stereotypies • Poor growth • Hypogonadism • Congenital anomalies • Mental retardation • Behavioural problems • Au

  53. Slide 53: Homeostatic perturbations change the system set-point

    Homeostatic perturbations change the system set - point thus making treatment more complicated compensatory state of the system GAIN OF FUNCTION LOSS OF F UNCTION OVER COMPENSATION system activity HIGH ACTIVITY LOW ACTIVITY OPTIMAL FUNCTION OVER COMPENSATION NORMAL changes due to stress/ disease are

  54. Slide 54: Epilepsy as a model disease for polymodal medicines

    EXCITOTOXICITY Epilepsy as a model disease to investigate the advantages of polymodal medicines Epilepsy Plasticity Inflammation Cell cycle AFFECTED “MODE” Synaptic control Anti - inflammation Cell death control THERAPEUTIC CONTROL Multi - target & Poly - modal treatment MODEL DISEASE

  55. Slide 55: Summary 1: the ideal pharmacological treatment

    Summary 1: the “ ideal ” pharmacological treatment for multi - factorial disorders • Should be a rationalised “multi - target” drug , or a combination of drugs , possibly designed using models predictive of both efficacy and safety . This clashes with the idea of target - selective drugs • Should be

  56. Slide 56: Plant cannabinoids: THC and the endocannabinoid system

    Plant cannabinoids : THC and the endocannabinoid system (ECS) O H 3 C H O ( - ) - D 9 - t e t r a h y d r o c a n n a b i n o l ( T H C , o i l ) THC E L L M 472 1 1 360 CB 1 , CB 2 Cannabinoid receptors Endocannabinoids

  57. Slide 57: Endocannabinoids and the regulation of their tissue levels

    Endocannabinoids and the regulation of their tissue levels 15 October 2014 57 Phospholipid - derived precursors Endocannabinoids Degradation products Endocannabinoids: 1 ) are produced “ on demand ” 2) activate cannabinoid CB 1 and CB 2 receptors locally 3) are immediately metabolized P h o s p h o

  58. Slide 58: Endocannabinoid regulation of homeostasis

    Endocannabinoid regulation of homeostasis at the cellular , tissue and systemic level

  59. Slide 59: Plant cannabinoids are multi-target

    Plant cannabinoids are multi - target High < 1µM Med 1 - 10µM Low > 10µM Med 1 - 10µM Low > 10µM High <1µM Activation Repression 5HT1Ac 5HT1Ar α 1 β Glycine CB2 α 1Glycine Ca GPR55 TRPA1 CB1 PPAR γ TRPM8 TRPV1 TRPV2 δ Opioid µOpioid High < 1µM Med 1 - 10µM Low > 10µM Med 1 - 10µM Low > 10µM High <1µ

  60. Slide 60: Plant cannabinoids are multi-modal pro-homeostatic compounds

    Plant cannabinoids are multi - modal pro - homeostatic compounds 60 Indeed , depending on the molecular mechanism of action , cell type and basal conditions of the cell , cannabinoids can both inhibit and stimulate : 1) mTOR and autophagy 2) mitochondrial function 3) ROS formation Not enough transmi

  61. Slide 61: Cannabidiol pharmacological fingerprint

    Cannabidiol pharmacological fingerprint “shakes hands” with the aethiopathology of epilepsy 15 October 2014 61 Keppra Valproate Cannabidiol CBD + Keppra CBD + Valproate AETIOPATHOPHYSIOLOGICAL FINGERPRINT POLYPHARMACOLOGICAL FINGERPRINT ACTIVATE TARGET REPRESS TARGET beneficial detrimental

  62. Slide 62: Two is better than one

    Two is better than one… .. 62 Preclinically : • THC+CBD more effective than THC alone in reducing glioma cell growth in the presence of temozolomide (Salazar et al. 2009) • CBD+CBG more potent than each alone at inhibiting human prostate and breast carcinoma cell growth ( unpublished ) Clinically :

  63. Slide 63: Cannabinoids are effective in epilepsy

    Cannabinoids are effective in epilepsy Epilepsy Plasticity Inflammation Cell cycle AFFECTED “MODE” Synaptic control Anti - inflammation Cell death control THERAPEUTIC CONTROL Cannabinoid treatment MODEL DISEASE

  64. Slide 64: If cannabinoids work with epilepsy, then...

    If cannabinoids work with epilepsy, then…. Epilepsy plasticity Immune response Cell life cycle Synaptic control Anti - inflammation Control cycle control Schizo . IBD Glioma AFFECTED “MODE” THERAPEUTIC CONTROL CURRENT PIPELINE Autism DMD NHIE FUTURE ORPHAN PIPELINE MODEL DISEASE

  65. Slide 65: Epilepsy and autism connected through synaptic plasticity

    Epilepsy and autism are connected through maladaptive alterations of synaptic plasticity Jensen et al (2011) Mutations associated with autism commonly disrupt tonic endocannabinoid signalling ( Foldy et al, 2013) ↑ endocannabinoids contribute to rare forms of Autism (e.g. fragile X syndrome) in anim

  66. Slide 66: Plant cannabinoids work in models of NHIE

    P lant cannabinoids work in models of neonatal hypoxic - ischemic encephalopathy (NHIE) • Recent novel approaches (NMDA antagonists, Ca 2+ blockers, anticonvulsants, antioxidants, anti - inflammatories etc) have been largely dissapointing Cannabinoids are able to bring many of these features into a

  67. Slide 67: Why plant cannabinoids may work in Duchenne's muscular dystrophy

    satellite cells myoblasts myotubes 1 2 Why plant cannabinoids may work in Duchenne’s muscular dystrophy • Endocannabinoids negatively control skeletal muscle differentiation via activation of CB 1 receptors (Iannotti et al., PNAS, 2014) at the level of: 67 • However, CB 1 activation also stimulates

  68. Slide 68: Conclusions

    Conclusions Epilepsy plasticity Immune response Cell life cycle Synaptic control Anti - inflammation Control cycle control Schizo . IBD Glioma AFFECTED “MODE” THERAPEUTIC CONTROL CURRENT PIPELINE Autism DMD NHIE FUTURE ORPHAN PIPELINE Cannabinoid treatment MODEL DISEASE

  69. Slide 69: Pipeline Overview

    Pipeline Overview Dr Stephen Wright, R&D Director 69

  70. Slide 70: Role of the Endocannabinoid System

    Role of the Endocannabinoid System (ECS) • ECS is not working through end stage single target pharmacology, but instead is working by restoring balance • Recruitment of endogenous systems that the body uses • Disease occurs at the edge of de - compensation • Opportunity to restore health is only whe

  71. Slide 71: Cannabinoid Activity in Unbalanced Systems

    Cannabinoid Activity in Unbalanced Systems 71 • Excitotoxicity and neuroprotection • Calcium / intracellular ion flows • Underlying inflammatory process • ROS production / scavenging • Anti - convulsive / epileptogenic • Energy management • Neuronal function / plasticity • Immunomodulation • Apoptos

  72. Slide 72: Our Pipeline

    Our Pipeline PHASE 3 IND OPEN, SPA ONGOING PHASE 3 DATA AROUND END 2014 PHASE 2 b TRIAL UNDERWAY PHASE 2 DATA PHASE 2 TRIAL TO COMMENCE H1 2015 PHASE 1b/2a TRIAL UNDERWAY PHASE 2a TRIAL UNDERWAY PHASE 2/3 IND, FAST TRACK, ORPHAN DESIGNATION NEXT STEP: APPLY FOR ORPHAN DESIGNATION Partnered Unpartner

  73. Slide 73: Current Phase Pipeline: Schizophrenia

    Current Phase 2 Pipeline 1. Schizophrenia

  74. Slide 74: Cannabinoids in Psychosis

    Cannabinoids in Psychosis • The ECS within the CNS is essential for normal mental health • CB 1 modulates release of dopamine / glutamate • eCBs levels negatively correlate with psychotic symptoms • ECS p rotects against underlying pathophysiology ( adaptive process ) • However - THC, psychoactive c

  75. Slide 75: Double-blind Clinical Trial (n=42)

    Double - blind , 4 Week Clinical Trial (n=42) • as effective as amisulpride in reducing positive symptoms ( Leweke et al, 2012 ) • more effective in reducing negative symptoms ( Leweke et al, 2012) • increases circulating endocannabinoids (protective) ( Leweke et al, 2012 ) Positive Symptoms CBD per

  76. Slide 76: GWP42003 Clinical Trials

    GWP42003 Clinical Trials A double - blind, randomised, placebo - controlled, parallel group study of GWP42003 as adjunctive therapy in the first line treatment of schizophrenia or related psychotic disorders. This study is currently recruiting. 1. GWP42003 as an add - on treatment in first - episode

  77. Slide 77: Treatment of Ulcerative Colitis

    2. Treatment of Ulcerative Colitis

  78. Slide 78: Why Inflammatory Bowel Disease?

    Why Inflammatory Bowel Disease? 78 Dysregulation of the endocannabinoid system in inflammation Evidence for utility of cannabinoids in literature and from collaborations Observations and anecdotal evidence from patient populations regarding the use of cannabis Promising signals of efficacy from GW s

  79. Slide 79: Cannabinoids Show Utility in IBD

    Cannabinoids Show Utility in IBD Evidence for additive effects of THC and CBD • CBD reduces DNBS induced inflammation (Borelli et al, 2009) • CBD restores cytokine induced increased permeability ( Alhamoruni et al, 2011) • CBD normalized LPS - induced motor disturbances (Lin et al, 2011) • In bi red

  80. Slide 80: DNBS induced colitis model: GWP42003 lead candidate

    • The following effects were observed in a model of DNBS induced colitis : GWP42003 extract Identified as Lead Candidate (contains 4% THC) # Inducible Free Radicals Indicates increased nitric oxide (active colonic inflammation) 80 Pro - and Anti - Inflammatory Cytokines Reduce pro - inflammatory cyt

  81. Slide 81: Phase 2a Ulcerative Colitis Trial Design

    Phase 2a Ulcerative Colitis Trial Design Randomised , double - blind , placebo - controlled parallel group, pilot: GWP42003 150mg – 250mg (BD) Placebo n=30 n=30 2 Weeks Screen V1 V2 Maintenance (8 Weeks) SCREENING TREATMENT END OF STUDY FOLLOW UP Dose Escalation Period (2 weeks) V3 V4 V5 V6 • Indica

  82. Slide 82: Patient Population

    Patient Population • All patients had failed to go into remission despite first line treatment with salicylates (and immunomodulators in some patients) • Mean age 44 years (range 19 to 72 years) • Mean duration of ulcerative colitis of 9 years (up to 42 years) • Baseline Mayo score of 7.2 (range 4 -

  83. Slide 83: Primary End Point – Induction of Remission

    Primary End Point – Induction of Remission 83 Intent to Treat Per Protocol 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% GWP42003 Placebo 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% GWP42003 Placebo 30% N=29 N=31 N=17 N=27 Failed to remit Remission with GWP42003 Remission with placebo n.s.s . n.s.s .

  84. Slide 84: Subject Global Impression of Change

    Subject Global Impression of Change 84 Intent to Treat Per Protocol GWP42003 Placebo better no change worse 80% 10% 10% 93% 6% 55% 26% 19% 60% 26% 15% P=0.003 P=0.03

  85. Slide 85: Inflammatory Bowel Disease Questionnaire

    Inflammatory Bowel Disease Questionnaire 85 0 20 40 60 80 100 120 140 160 180 200 GWP42003 Placebo p er p rotocol N=17 N=27 baseline Treated with GWP42003 Treated with placebo P=0.06

  86. Slide 86: Physician Assessment of Disease

    Physician Assessment of Disease 86 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Before After Before After 0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2 gwp42004 placebo Impression of Severity (per protocol) Global Assessment of Illness Severity (per protocol) normal mild moderate severe GWP42003 Placebo Seve

  87. Slide 87: Safety

    Safety • No Serious Adverse Events on GWP42003 Cf 4 SAEs on placebo (2 flare - ups of UC, chest pain and pregnancy) • No deaths on the study • 100% of patients on GWP42003 had non - serious AES Compared with 70% on placebo Most common AEs were dizziness (41%): somnolence (34%); disturbance in attent

  88. Slide 88: Conclusions

    Conclusions • The study provides good evidence of efficacy in patients who were able to tolerate the treatment • The high rate of early withdrawals due to adverse events on active treatment is likely to be due to over - aggressive dose titration and an excess of THC - related issues • This relativel

  89. Slide 89: Glioma Multiforme

    3. Glioma Multiforme

  90. Slide 90: Rationale for Cannabinoids in Oncology

    Rationale for Cannabinoids in Oncology The Endocannabinoid System (CB receptors, TRP channels etc.) experiences changes in expression 90 ECS cannabinoids Life Cycle differentiation/ cell cycle/proliferation Kogan et al, 2005 Aguado et al, 2007 Sarfaraz et al, 2006, 2008 Marcu et al, 2010, McAllister

  91. Slide 91: THC + CBD + TMZ in Different Xenograft Cell Lines

    THC + CBD + TMZ in Different Xenograft Cell Lines (in vivo) CBD + THC + TMZ was as potent as THC + TMZ at 50% of the dose of THC THC + CBD + TMZ was as potent as THC + TMZ at 25% of the dose of THC 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 VEH 0 2 4 6 8 10 12 1 2 3 4 5 6 7 8

  92. Slide 92: Glioma: Cannabinoids Effective as an Oral Treatment

    Glioma: Cannabinoids (THC + CBD) are Effective as an Oral Treatment vehicle THC:CBD TMZ TMZ+THC:CBD 20 25 30 35 40 45 0 20 40 60 80 100 % Survival Days • Oral route of administration is as effective as peri - tumoral administration • Effect of tumour regression can be correlated with cannabinoid con

  93. Slide 93: Phase Ib/2a Study Design

    Phase Ib /2a Study Design 365 DAYS 14 DAYS 28 DAYS Open Label Phase (N=6) Randomisation Phase (N=20) Eligibility Period Open - Label Phase: Two cohorts of three patients each will receive Sativex® and DIT. Cohort 2 starts after visit 5 for Cohort 1 is complete & treatment deemed safe Stable TMZ + Sa

  94. Slide 94: Diabetes mellitus

    4. Diabetes mellitus 15 October 2014 94

  95. Slide 95: GWP42004 Effective in Diabetic Models

    GWP42004 Effective in Diabetic Models • GWP42004 protects islet function: rodent diabetes model ( not seen with typical CB 1 antagonists) GWP42004 Sacrificed at week 6 Normal Vehicle GWP42004 Vehicle Sacrificed at week 6 Normal Sacrificed at week 0 Beta cell protection ( db/db mouse) Time (minutes)

  96. Slide 96: Exploratory Phase 2A Study Key Findings

    -5 -4 -3 -2 -1 0 1 2 3 4 -1.2 -1 -0.8 -0.6 -0.4 -0.2 0 0.2 0.4 Exploratory Phase 2A Study Key Findings Change from Baseline in Fasting Glucose ( mmol /L) Placebo 5mg 42004 Mean Change from Baseline ( mmol /L) p = 0.0407 96 Change from Baseline in Mean serum IL - 6 Levels ( ng /mL) p = 0.0764 Mean Ch

  97. Slide 97: Phase 2 Dose Ranging Trial: Study Design

    Safety Follow up GWP42004 2mg: n = 50 RANDOMISATION END OF TREATMENT END OF STUDY SCREENING 1 Week 12 Weeks 1 week GWP42004 5mg: n = 50 GWP42004 15mg: n = 50 Placebo : n = 50 Visit 3 Visit 2 Visit 5 Visit 1 Visit 4 Baseline Phase 2 Dose Ranging Trial : Study Design

  98. Slide 98: Phase II, Dose-ranging RCT

    Phase II, Dose - ranging RCT Placebo 2mg GWP42004 5mg GWP42004 15mg GWP42004 ( all twice daily) Primary: • To evaluate the efficacy of 2, 5 and 15 mg twice daily of GWP42004 compared with placebo by assessing the impact of treatment on glycaemic control in the treatment of participants with Type 2 d

  99. Slide 99: GWP42006 (CBDV) Epilepsy

    GWP42006 (CBDV) Epilepsy 15 October 2014 99

  100. Slide 100: Progress to date

    Progress to date • Pre - clinical profile shows a broad spectrum of anti - seizure activity Different profile from Epidiolex® • Pre - clinical pharmacology and toxicology shows a benign toxicology profile • Phase 1 single rising dose and multiple dose oral and IV pharmacokinetics study completed Pk

  101. Slide 101: Sativex

    Sativex 15 October 2014 101

  102. Slide 102: Sativex in Advanced Cancer Pain Overview

    Sativex in Advanced Cancer Pain Overview • Add - on treatment of persistent pain in people with advanced cancer who experience inadequate pain relief from optimized chronic opioid therapy ▪ 420k patients in the U.S. • Substantial body of positive Phase 2 data ▪ Phase 2a study (n=177) published - Jou

  103. Slide 103: Advanced Cancer Pain: Phase 2b Dose Ranging Study

    n =120 n =120 n =120 Advanced Cancer Pain: Phase 2b Dose Ranging Study (n=360) 35 DAYS 5 - 14 DAYS 14 DAYS Opioid + Sativex or Placebo 1 - 4 sprays / day SCREENING RANDOMISATION END OF TREATMENT 5 - 14 days to obtain 3 day baseline period Sativex Placebo Opioid + Sativex or Placebo 6 - 10 sprays / d

  104. Slide 104: Phase 2b Combined Low & Mid Dose Groups Responder Analysis

    Phase 2b Combined Low & Mid Dose Groups, ITT Cumulative Proportion of Responders Analysis * 3 - 10 sprays single dose group employed in the phase 3 studies * 104 Percent of Patients Improved Percent Improvement in Pain from Baseline

  105. Slide 105: Phase 2a Cumulative Proportion of Responders Analysis

    Phase 2a, ITT Cumulative Proportion of Responders Analysis (n=60) (n=59) 105 Percent of Patients Improved Percent Improvement in Pain from Baseline

  106. Slide 106: Two Core Phase 3 Trials: Trial Design

    n=190 Two Core Phase 3 Trials: Trial Design (n=380) 35 DAYS 5 - 14 DAYS 14 DAYS Opioid + Sativex 3 - 10 sprays/day Opioid + Placebo 3 - 10 sprays/day SCREENING RANDOMISATION END OF TREATMENT EXTENSION STUDY Primary Efficacy Analysis Key Secondary Endpoints 5 - 14 days to obtain 3 day baseline period

  107. Slide 107: Sativex in MS Spasticity: Positive Phase 3 Data

    Sativex in MS Spasticity: Positive Phase 3 Data ( Novotna et al, 2011) • Positive primary endpoint (p=0.0002) • Range of positive secondary endpoints Sleep (p<0.0001) Spasm ( p=0.0046) Responder analysis (p=0.0003) Physician GIC ( p=0.005) Carer GIC ( p=0.005) Patient GIC (p=0.023) Barthel ADL Index

  108. Slide 108: Sativex in MS Spasticity Overview

    ECTRIMS 2013 Congress Sativex in MS Spasticity Overview • Approved in 27 countries ( principally in EU) • Indication: Treatment of MS spasticity in patients who have failed to respond to other anti - spasticity medication • Phase 3 IND opened with FDA • SPA process ongoing for single additional Phas

  109. Slide 109: Sativex in Cerebral Palsy

    Sativex in Cerebral Palsy • Trial underway to evaluate Sativex in children (8 to 18 years) with spasticity due to cerebral palsy or traumatic central nervous system injury who have not responded adequately to their existing anti - spasticity medications • 72 children to be recruited into parallel gr

  110. Slide 110: Sativex in Neuropathic Pain

    0.00 0.50 1.00 1.50 2.00 2.50 3.00 Sativex Placebo 0.0 0.5 1.0 1.5 2.0 Sativex Placebo Sativex in Neuropathic Pain Phase 2 Data and Preclinical Promise Neuropathic Pain in Multiple Sclerosis Peripheral Neuropathic Pain p=0.004* p =0.005* Reduction Pain NRS score from Baseline Improvement in NRS Pain

  111. Slide 111: Emerging Pipeline

    Emerging Pipeline 15 October 2014 111

  112. Slide 112: Same Rationale for CBs in Behavioural Encephalopathies

    Same Rationale for CBs in Behavioural Encephalopathies / Neuroprotection 112 Cannabinoids Modulation of the ECS Anti - inflammation Neuronal Plasticity Mitochondrial protection Social behaviour endocannabinoid levels are altered in autism Reverse inflammation associated with excitotoxicity & ischemi

  113. Slide 113: Epilepsy = Model CB Responsive Disease

    Epilepsy = Model CB Responsive Disease Neurotoxicity with behavioural complications Neural plasticity Inflammatory response Neurotoxicity Synaptic control Anti - inflammation Control cell survival Cannabinoid treatment AFFECTED SYSTEM THERAPEUTIC CONTROL MODEL DISEASE THE ECS HAS A FUNDAMENTAL ROLE

  114. Slide 114: The spectrum of cannabinoid pharmacology

    The spectrum of cannabinoid pharmacology Neurotoxicity with behavioral complications Neural plasticity Inflammatory response Neurotoxicity Synaptic control Anti - inflammation Control cell survival Cannabinoid treatment Schizo - phrenia IBD Glioma AFFECTED SYSTEM THERAPEUTIC CONTROL CURRENT PIPELINE

  115. Slide 115: Concluding Remarks

    Concluding Remarks Dr Geoffrey W Guy, Chairman & Founder October 2014

  116. Slide 116: GW…The Story So Far

    GW…The Story So Far • Over 16 years we have created a unique platform dedicated to advancing cannabinoid science Discovery of novel cannabinoid pharmacology Validated through extensive body controlled clinical trials Track record of regulatory success In - house expertise across R&D and manufacture

  117. Slide 117: Emerging Pipeline – Scientific Foundation

    Emerging Pipeline – Scientific Foundation • Systems - based approach • Endocannabinoid system provides fundamental autoregulatory homeostatic mechanisms • Protection and maintenance of neurological function Compensating perturbation – pathological phenotype Neural plasticity • Epilepsy and inflammat

  118. Slide 118: Future Directions

    Future Directions • Intellectual development • Cognitive impairment Executive function Visual/verbal/episodic memory Semantic memory • Sleep • Behaviour • Language • Attention/vigilance • Neuropsychiatric conditions • Neurological dysfunction • Expansion into non - CNS disease 118 GW: World leaders

GW Pharmaceuticals — Investor Day (October 2014) on 6ix